GM2 ganglioside antigen (GM2)

GM2 ganglioside antigen is a complex glycosphingolipid found predominantly in the outer leaflet of plasma membranes. Its structure consists of a ceramide lipid tail embedded within the membrane and an extracellular carbohydrate chain containing sialic acid, galactose, N-acetylglucosamine, glucose, and N-acetylgalactosamine residues. It plays critical roles in cell signaling pathways that regulate proliferation, differentiation, apoptosis, neuronal development—including neurite outgrowth—and immune responses such as inflammation and immune cell migration. GM2 is notably overexpressed on various human cancers where it serves as an important tumor-associated carbohydrate antigen. This makes it an attractive target for experimental cancer immunotherapies including anti-GM2 CAR-T cells. In addition to its role in oncology, defective degradation or accumulation of GM2—due to mutations affecting β‐hexosaminidase A/B or the activator protein—leads to severe neurodegenerative lysosomal storage diseases such as Tay-Sachs disease and Sandhoff disease. Therapeutic strategies targeting this molecule must consider potential safety issues arising from its presence on normal neural tissues. The use of anti-GM2 antibodies or engineered T-cells has shown promise preclinically but requires careful monitoring for adverse effects related to autoimmunity or neurotoxicity.[1][4][6]

Other names

Ganglioside GM2G(M2) gangliosideGM2 antigenOFA-I-1 (as a tumor antigen)[7]N-acetyl-beta-D-galactosaminyl-(1->4)-alpha-N-acetylneuraminosyl-(2->3)-beta-D-galactosyl-(1->4)-beta-D-glucosyl-N-acylsphingosine[4]

For CAR-T therapy: Engineered T cells recognize and kill tumor cells expressing GM2 on their surface via antibody-mediated recognition of the glycolipid epitope.[6][7]